Tags

Type your tag names separated by a space and hit enter

Age-related macular degeneration (AMD): pathogenesis and therapy.
Pharmacol Rep 2006 May-Jun; 58(3):353-63PR

Abstract

Age-related macular degeneration (AMD) is a disease leading to severe visual loss and legal blindness in the elderly population. Its pathogenesis, likely multifactorial, involving a complex interaction of metabolic, functional, genetic and environmental factors, remains poorly understood. For these reasons currently used therapeutic approaches are insufficiently effective. Although major abnormalities are seen in four functionally interrelated tissues, i.e., photoreceptors, retinal pigment epithelium (RPE), Bruch's membrane and choriocapillaries, the impairment of RPE cell functions is an early and crucial event in the molecular pathways leading to clinically relevant AMD changes. RPE progressively degenerate, which results in a progressive irreversible degeneration of photoreceptors. Four processes: lipofuscinogenesis, drusogenesis, inflammation and neovascularization, specifically contribute to the development of two forms of AMD, the dry form (non-exudative; geographic atrophy) and the wet form (exudative, neovascular). This paper briefly describes major molecular and cellular events leading to AMD, and presents currently used and new experimental, forthcoming therapeutic strategies.

Authors+Show Affiliations

Department of Pharmacology, Medical University, Zeligowskiego 7/9, PL 90-752 Łódź, Poland. jznowak@pharm.am.lodz.pl

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

16845209

Citation

Nowak, Jerzy Z.. "Age-related Macular Degeneration (AMD): Pathogenesis and Therapy." Pharmacological Reports : PR, vol. 58, no. 3, 2006, pp. 353-63.
Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58(3):353-63.
Nowak, J. Z. (2006). Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacological Reports : PR, 58(3), pp. 353-63.
Nowak JZ. Age-related Macular Degeneration (AMD): Pathogenesis and Therapy. Pharmacol Rep. 2006;58(3):353-63. PubMed PMID: 16845209.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Age-related macular degeneration (AMD): pathogenesis and therapy. A1 - Nowak,Jerzy Z, PY - 2006/02/21/received PY - 2006/04/26/revised PY - 2006/7/18/pubmed PY - 2006/12/29/medline PY - 2006/7/18/entrez SP - 353 EP - 63 JF - Pharmacological reports : PR JO - Pharmacol Rep VL - 58 IS - 3 N2 - Age-related macular degeneration (AMD) is a disease leading to severe visual loss and legal blindness in the elderly population. Its pathogenesis, likely multifactorial, involving a complex interaction of metabolic, functional, genetic and environmental factors, remains poorly understood. For these reasons currently used therapeutic approaches are insufficiently effective. Although major abnormalities are seen in four functionally interrelated tissues, i.e., photoreceptors, retinal pigment epithelium (RPE), Bruch's membrane and choriocapillaries, the impairment of RPE cell functions is an early and crucial event in the molecular pathways leading to clinically relevant AMD changes. RPE progressively degenerate, which results in a progressive irreversible degeneration of photoreceptors. Four processes: lipofuscinogenesis, drusogenesis, inflammation and neovascularization, specifically contribute to the development of two forms of AMD, the dry form (non-exudative; geographic atrophy) and the wet form (exudative, neovascular). This paper briefly describes major molecular and cellular events leading to AMD, and presents currently used and new experimental, forthcoming therapeutic strategies. SN - 1734-1140 UR - https://www.unboundmedicine.com/medline/citation/16845209/Age_related_macular_degeneration__AMD_:_pathogenesis_and_therapy_ L2 - http://www.if-pan.krakow.pl/pjp/pdf/2006/3_353.pdf DB - PRIME DP - Unbound Medicine ER -